TABLE 8.
Group | Formulation | Active compound | Vehicle | Administration route | Treatment regimen |
---|---|---|---|---|---|
1 | Untreated control | None | None | None | None |
2 | AmBisome | Amphotericin B | Dextrose (5%) | Intravenous | 25 mg/kg of body wt b.i.d., 5 doses |
3 | Leshcutan | Paromomycin sulfate (15%) | Methylbenzethonium chloride (12%) in petrolatum | Topical | 0.1 ml 2 times/day for 10 days |
4 | Vehicle control | NA | E-PG (1:1) | Topical | 50 μl 2 times/day for 10 days |
5 | Topical formulation 1 | LSH001 | Saturated drug solution in E-PG (1:1) | Topical | 50 μl 2 times/day for 10 days |
6 | Topical formulation 2 | LSH002 | Saturated drug solution in E-PG (1:1) | Topical | 50 μl 2 times/day for 10 days |
7 | Topical formulation 3 | LSH003 | Saturated drug solution in E-PG (1:1) | Topical | 50 μl 2 times/day for 10 days |
8 | Oral formulation 1 | LSH001 | Standard suspended vehicle | Oral | 25 mg/kg 2 times/day for 10 days |
9 | Oral formulation 2 | LSH002 | Standard suspended vehicle | Oral | 25 mg/kg 2 times/day for 10 days |
10 | Oral formulation 3 | LSH003 | Standard suspended vehicle | Oral | 25 mg/kg 2 times/day for 10 days |
b.i.d., twice a day; NA, not applicable.